1. Home
  2. PGEN vs NNNN Comparison

PGEN vs NNNN Comparison

Compare PGEN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.24

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$34.72

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
NNNN
Founded
1998
2021
Country
United States
Germany
Employees
N/A
27
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PGEN
NNNN
Price
$4.24
$34.72
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$8.33
N/A
AVG Volume (30 Days)
3.0M
12.8K
Earning Date
05-13-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$230,981,000.00
N/A
Revenue This Year
$1,115.92
N/A
Revenue Next Year
$81.04
N/A
P/E Ratio
N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$7.50
52 Week High
$5.47
$55.65

Technical Indicators

Market Signals
Indicator
PGEN
NNNN
Relative Strength Index (RSI) 52.41 69.71
Support Level $3.97 $26.31
Resistance Level $4.40 $38.00
Average True Range (ATR) 0.25 2.85
MACD -0.01 0.71
Stochastic Oscillator 30.98 98.98

Price Performance

Historical Comparison
PGEN
NNNN

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: